myBRCA HiRisk is a multi-gene test to screen for hereditary breast and ovarian cancer risk.

The BRCA genes are part of your body’s natural defense system. They help protect you from developing cancer.

WHY BRCA GENES ARE IMPORTANT
If you have a BRCA gene that is not working properly (meaning, it carries a harmful variant), your lifetime risk of developing breast, ovarian and other cancers increases significantly.

myBRCA HiRisk is a screening test that identifies variants in 26 genes, including BRCA1 and BRCA2, which are associated with increased risk for developing breast, ovarian, and other cancer types.

WHO SHOULD GET SCREENED
You might consider myBRCA HiRisk if you or one of your close relatives* has one or more of the following:

» Breast cancer at or before age 50
» Two or more primary breast cancers in the same individuals
» Ovarian cancer, fallopian tube cancer or primary peritoneal cancer
» Male breast cancer
» Three or more of the following cancers: breast, ovarian, fallopian tube, primary peritoneal, endometrial, pancreatic, prostate, thyroid, colorectal, sarcoma, adrenocortical carcinoma, brain, leukemia, gastrointestinal polyps, gastric, melanoma, and/or kidney
» A blood relative with a known cancer-causing variant

*Close blood relatives: first-degree (parents, children, siblings), second-degree (grandparents, aunts/uncles, nieces/nephews, half siblings), and third degree (first cousins, great aunts/uncles/grandparents)

POSSIBLE OUTCOMES
» Any result, negative, positive, or inconclusive, should become a part of how you and your physician evaluate your health and clinical needs
» For an explanation of how myBRCA HiRisk testing works and what your potential outcomes could mean for you, please visit our website.
WHAT YOU WILL GET
» A report with results provided to your physician
» A complimentary call with one of our genetic counselors to review your results upon request (currently applies to U.S. only)
» Insights to help you and your physician determine the most appropriate preventive, clinical, and lifestyle considerations based on your hereditary risk
» Comprehensive analysis of 26 genes associated with hereditary breast and ovarian cancer

ADDITIONAL TEST DETAILS
The myBRCA HiRisk test screens these 26 genes:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Gene</th>
<th>Gene</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATM</td>
<td>CDH1</td>
<td>MRE11A</td>
<td>PMS2</td>
</tr>
<tr>
<td>BARD1</td>
<td>CHEK2</td>
<td>MSH2</td>
<td>PTEN</td>
</tr>
<tr>
<td>BLM</td>
<td>EPCAM</td>
<td>MSH6</td>
<td>RAD50</td>
</tr>
<tr>
<td>BRCA1</td>
<td>FAM175A</td>
<td>MUTYH</td>
<td>RAD51C</td>
</tr>
<tr>
<td>BRCA2</td>
<td>MEN1</td>
<td>NBN</td>
<td>RAD51D</td>
</tr>
<tr>
<td>BRIP1</td>
<td>MLH1</td>
<td>PALB2</td>
<td>STK11</td>
</tr>
</tbody>
</table>

These genes may be associated with increased risk for:

**Hereditary Cancer Syndromes**
- Cowden Syndrome
- Li-Fraumeni Syndrome
- Peutz-Jeghers Syndrome
- Lynch Syndrome

**Cancer Types**
- Colorectal Cancer
- Endometrial Cancer
- Melanoma
- Pancreatic Cancer
- Gastric Cancer + Others

*This test is not intended to screen comprehensively for all cancers.*

WHAT YOU WILL LEARN
» Help you understand your risk of developing breast, ovarian, and other cancer types
» Help identify potentially at-risk family members
» Improve the odds of early detection and prevention
» Help guide management and/or treatment options depending on which genes are involved

HOW TO GET STARTED
» You talk with your physician about myBRCA HiRisk. After we receive your physician’s order, we send you a link to a secure payment site
» Once we receive your sample, we process it at our CLIA-certified lab and provide results within 3 to 4 weeks
» We let you and your physician know that your results are ready on our secure site

TECHNICAL INFORMATION
» Targeted next generation sequencing assay for 26 hereditary cancer genes
» Point variants and small insertions/deletions are detected (>99.9% sensitivity and specificity), large rearrangement and deletion/duplication analysis are also performed
» Likely pathogenic or pathogenic intronic variants up to 10 base pairs from the coding region are always reported
» Laboratory developed test (LDT) performed in a CLIA-certified laboratory (CLIA #22D2089381) following LDT regulations
» Variant classification based on American College of Medical Genetics and Genomics Guidelines
» PMS2 pseudogene analysis included